Royal Joh. Enschedé
Gelmer Leibbrandt has extensive experience in the pharmaceutical and biopharma industries, holding various leadership roles in companies such as Teva Pharmaceuticals Europe BV, Nobilon (part of Schering-Plough), and Sanquin. With a background in economics and an e-MBA from New York Institute of Technology, Gelmer has demonstrated strong strategic and operational capabilities in roles such as CEO, Director of Strategy & Operations, and General Manager. Their accomplishments include launching the first BioSimilar to Neulasta on the EU market and leading culture change programs within organizations. Gelmer's expertise in marketing, sales, and brand management has been instrumental in the growth and success of the companies Gelmer has been a part of.
This person is not in any teams
Royal Joh. Enschedé
Royal Joh. Enschedé started out as a small book printer in 1703 and grew into a major company in Harlem. Royal Joh. Enschedé is internationally known for its attractive banknotes and stamps. With special attention to details, technical expertise and quality, Royal Joh. Enschedé is the specialist for special, secure and highly trustworthy print work as well as security solutions. Royal Joh. Enschedé supports products for financial transactions, cash equivalent and certified products such as visas, tax labels, stamps, diplomas, certificates as well as products for the protection of branded products (brand protection). Strengthened by our world-class security printing expertise, we provide anti-fraud and anti-counterfeiting solutions tailored to the specific wishes of our clients.